Trademark Snap Shot Amendment & Mail Processing Stylesheet (Table presents the data on Amendment & Mail Processing Complete) |
|||
OVERVIEW |
|||
SERIAL NUMBER | 90240882 | FILING DATE | 10/07/2020 |
REG NUMBER | 0000000 | REG DATE | N/A |
REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
INTL REG # | N/A | INTL REG DATE | N/A |
TM ATTORNEY | RHIM, ANDREW |
L.O. ASSIGNED | 101 |
PUB INFORMATION |
|||
RUN DATE | 08/07/2021 | ||
PUB DATE | N/A | ||
STATUS | 680-APPROVED FOR PUBLICATION | ||
STATUS DATE | 08/06/2021 | ||
LITERAL MARK ELEMENT | TYCRUVA | ||
DATE ABANDONED | N/A | DATE CANCELLED | N/A |
SECTION 2F | NO | SECTION 2F IN PART | NO |
SECTION 8 | NO | SECTION 8 IN PART | NO |
SECTION 15 | NO | REPUB 12C | N/A |
RENEWAL FILED | NO | RENEWAL DATE | N/A |
DATE AMEND REG | N/A |
FILING BASIS |
|||||
FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
44D | NO | 44D | NO | 44D | NO |
44E | NO | 44E | NO | 44E | NO |
66A | NO | 66A | NO | ||
NO BASIS | NO | NO BASIS | NO |
MARK DATA |
|
STANDARD CHARACTER MARK | YES |
LITERAL MARK ELEMENT | TYCRUVA |
MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
PARTY TYPE | 10-ORIGINAL APPLICANT |
NAME | Bristol-Myers Squibb Company |
ADDRESS | 430 E. 29th Street, 14th Floor New York, NY 10016 |
ENTITY | 03-CORPORATION |
CITIZENSHIP | Delaware |
GOODS AND SERVICES |
|
INTERNATIONAL CLASS | 005 |
DESCRIPTION TEXT | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing |
GOODS AND SERVICES CLASSIFICATION |
|||||||
INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
CHANGE IN REGISTRATION | NO |
TRANSLATION | The word(s) "TYCRUVA" has no meaning in a foreign language. |
PROSECUTION HISTORY |
||||
DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
08/06/2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 014 |
08/06/2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | 013 |
08/06/2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 012 |
08/06/2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | 011 |
08/06/2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | 010 |
07/27/2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 009 |
07/26/2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 008 |
07/26/2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 007 |
01/28/2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 006 |
01/28/2021 | GNRT | F | NON-FINAL ACTION E-MAILED | 005 |
01/28/2021 | CNRT | R | NON-FINAL ACTION WRITTEN | 004 |
01/27/2021 | DOCK | D | ASSIGNED TO EXAMINER | 003 |
11/21/2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
10/10/2020 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
ATTORNEY | Xiomara Triana |
CORRESPONDENCE ADDRESS | Xiomara Triana BRISTOL-MYERS SQUIBB COMPANY P.O. BOX 4000 TRADEMARKS DEPT., MAILSTOP D4243 PRINCETON, NJ 08648-4000 |
DOMESTIC REPRESENTATIVE | NONE |